{"filings":[{"id":99375,"accession_number":"0001437749-26-014996","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo CEO holds Discord town hall; transcript filed as 8-K","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dennis Calvert participated in a May 5, 2026 town hall on Discord; transcript and investor summary furnished.","No material financial or operational updates disclosed in the filing text or partial transcript excerpts.","Investor summary attached as Exhibit 99.2 is an image; specific figures are not extractable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99374,"accession_number":"0001437749-26-014540","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo CEO to host town hall on Discord May 5; transcript to follow","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Town hall on May 5, 2026 at 1:00 PM PT hosted on BioLargo Shareholder Discord channel.","CEO Dennis Calvert to provide brief company update and Q&A with shareholders.","Meeting will be recorded and transcript filed via 8-K before market open on May 6.","Questions can be pre-submitted in Discord channel #townhall-questions-may-5-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115332,"accession_number":"0001437749-26-009813","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.","Draws limited to $500K per notice; pricing equals avg of two lowest closing prices in prior 8 trading days; min $25K.","BioLargo issued 500,000 commitment shares to Clearthink as consideration; no cash proceeds from those shares.","Clearthink prohibited from short selling or hedging during term; beneficial ownership capped at 9.99%.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115331,"accession_number":"0001437749-26-007044","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.","Net loss of $15.2M vs. $4.3M in prior year; cash balance $3.9M at year end.","Engineering services revenue from third parties grew 98% to $2.0M.","Subsidiary Clyra Medical secured first stocking order for ViaCLYR wound irrigation solution.","PFAS treatment system installed in New Jersey; PFAS breakthrough featured in Chemical Engineering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131747,"accession_number":"0001437749-25-035506","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioLargo issues 624,383 shares to officers for salary; locked until $40M revenue or $300M cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two officers converted $99,901 of unpaid salary/expenses into 624,383 shares at $0.16/share.","Shares locked until BioLargo reports consolidated gross revenue ≥$40M, market cap >$300M, or change of control.","Conversion reduces near-term cash outflow and ties officer compensation to long-term company milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131746,"accession_number":"0001437749-25-035203","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo to present investor webcast on Nov 14, 2025 with slides attached","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor webcast scheduled for Nov 14, 2025 at 1:30 PM PT.","Slide deck attached as Exhibit 99.1 (image format) contains business update.","No financial or operational details from slides provided in text form."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131745,"accession_number":"0001437749-25-031354","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents at LD Micro Main Event; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company presented slides at LD Micro Main Event on October 20, 2025 in San Diego.","Slides contain company overview and forward-looking statements; no specific financial guidance or operational updates.","Presentation is routine investor relations activity; no changes to business outlook or strategy announced.","No quantitative data, contract wins, or milestone achievements were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148329,"accession_number":"0001437749-25-029852","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.02","2.06","7.01","9.01"],"status":"ready","headline":"BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.","BioLargo expects substantial impairment of its $3.486M note receivable from Pooph on its June 30 balance sheet.","Pooph claims it independently developed a new formula and is terminating the manufacturing agreement, which BioLargo contests as breach.","Pooph's products powered by BioLargo tech reached annual sales over $50M; BioLargo will pursue new odor-control market opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148328,"accession_number":"0001437749-25-027100","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents slides at investor conference; no material new details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slides were presented at a webcast investor conference on August 15, 2025 at 8:00 AM PT.","Exhibit 99.1 slide deck is incorporated by reference but no specific financial or operational data is provided in the filing body.","No new earnings, guidance, or business updates are disclosed in the 8-K or exhibit text.","Presentation content is furnished under Regulation FD and not deemed filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148327,"accession_number":"0001437749-25-023293","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.","Cellinity battery signed four MOUs with JV partners; each factory >$100M build, $500M annual revenue capacity; targets enterprise value >$2B.","First paid PFAS treatment project in New Jersey underway; AEC removes PFAS below 4 ppt; CEO named to U.S. Dept of Commerce ETTAC.","ONM (Pooph) sales decline led to increased AR, lower cash, downward stock pressure; payback arrangement and new Pooph ads launched.","BLEST engineering revenues grew 152% YoY in Q1 2025; potential multimillion-dollar projects in pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167106,"accession_number":"0001437749-25-021276","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"BioLargo shareholders approve reverse split authorization; board has no immediate plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected, including Dennis Calvert, Kenneth Code, Linda Park.","Advisory say-on-pay passed with 54.7% of votes present (103.9M for, 7.9M against).","Ratification of Hacker Johnson & Smith as auditor approved with 99.3% for.","Reverse stock split authorized (51.8% of outstanding shares) but board has no immediate plans to implement.","CEO states reverse split would only be used if needed to meet minimum price for Nasdaq/NYSE uplisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167105,"accession_number":"0001437749-25-017258","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents at investor webcast; no financial details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck presented at webcast investor conference on May 15, 2025 at 1:30 PM PT.","Filing contains no specific financial or operational updates; exhibit is an image slide deck.","No revenue, earnings, or guidance figures disclosed in the 8-K or text of the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184471,"accession_number":"0001437749-25-010296","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.","Net loss $4.347M, down 6% YoY; $3.490M of loss from Clyra Medical operations.","Issued 42% fewer shares in 2024 vs 2023; cash and equivalents $3.548M at Dec 31.","Clyra surgical irrigation products progressing toward national rollout with distribution partner.","Non-cash expenses (stock/options) $2.479M, representing 57% of net loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3269000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201059,"accession_number":"0001437749-24-035426","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.","Net loss narrowed to $1.1M in Q3 (from $1.5M) and $2.6M YTD (from $3.6M).","Current assets $7.4M, cash $3.9M; stockholders' equity $6.0M as of Sept 30, 2024.","CEO says tenth consecutive year of record revenue; expects 2025 to be another record.","Investing in production for national rollout of Clyra Medical Technologies products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":14122000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217077,"accession_number":"0001437749-24-026919","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo files slide deck from May 2024 conference; no new material data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation from a May 14, 2024 investor webcast is now filed on Form 8-K.","No financial results, guidance, or operational milestones are included in the filing.","Slides contain forward-looking statements and company overview, but no specific new facts.","Company remains listed on OTCQX under ticker BLGO; no business changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236840,"accession_number":"0001437749-24-020750","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BioLargo shareholders elect all seven directors, approve executive compensation, auditor, and 2024 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: Dennis Calvert, Kenneth Code, Dennis Marshall, Joseph Provenzano, Jack Strommen, Linda Park, Christina Bray.","Each director received >95M votes for; broker non-votes ~75M.","Advisory vote on exec compensation approved with 96.5% for (94.2M for, 3.5M against, 0.9M abstain).","Ratification of auditor Hacker Johnson & Smith approved with 98.9% for; 2024 Equity Incentive Plan adopted with 98.9% for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236839,"accession_number":"0001437749-24-020181","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents slides at annual meeting; no extractable data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Annual stockholder meeting held June 13, 2024; presentation slides furnished.","Slides are not reproduced in text; no specific financial or operational details available.","Filing discloses only that slides were presented; no material new facts reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236838,"accession_number":"0001437749-24-016762","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports record Q1 revenue, positive operating cash flow of $481K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.","Net loss $775K including $623K non-cash equity comp; stockholder's equity rose from $4.2M to $5.1M.","Launched water equipment subsidiary for PFAS treatment; appointed Sally Gutierrez, Jeffrey Kightlinger, Larry Dick to board.","EPA finalized PFAS regulations expected to favor BioLargo's treatment technology due to high efficacy and low waste."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4760000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254450,"accession_number":"0001437749-24-001796","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo Doubles Annual Revenues for Second Consecutive Year in 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 annual revenues more than doubled 2022, driven by Pooph pet odor control product sales.","Pooph sold through Amazon, Walmart, Chewy; BioLargo is technology partner to Pooph, Inc.","Expects first PFAS treatment technology revenues in 2024 after securing a municipal drinking water project.","Preliminary 2023 revenue estimates subject to audit; annual report expected by end of March."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254449,"accession_number":"0001437749-24-001078","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo to present at EmergingGrowth.com investor conference; no financial results disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company will present slide deck at webcast conference on January 10, 2024, 9:00 AM PT.","Slides attached as exhibit but not provided in searchable text; no specific data available.","Filing is a routine Regulation FD disclosure; no new earnings, guidance, or operational metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254448,"accession_number":"0001437749-24-000717","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BioLargo dismisses Haskell & White, engages Hacker Johnson as auditor for FY 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit committee approved Hacker Johnson & Smith PA as independent auditor for fiscal 2023, effective immediately.","Haskell & White LLP was dismissed as auditor on January 2, 2024.","No disagreements or reportable events occurred during fiscal years 2021, 2022, or subsequent interim period.","Company provided disclosure to Haskell & White, which agreed via letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271928,"accession_number":"0001437749-23-032675","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo holds earnings call Nov 20; no financial details in 8-K","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["BioLargo presented slides at its earnings call on November 20, 2023 at 3:00 PM PT.","The slides were furnished as Exhibit 99.1 but are not reproduced in text form in the filing.","No specific financial results, guidance, or material updates are disclosed in this 8-K.","Investors would need to refer to the slide deck for any earnings details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":7860000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271927,"accession_number":"0001437749-23-027617","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents at LD Micro investor conference on October 4, 2023","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation slides furnished as Exhibit 99.1; no financial results disclosed in filing.","Conference hosted by LD Micro at Luxe Sunset Boulevard Hotel, Los Angeles.","Item 7.01 Regulation FD disclosure; slides not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309446,"accession_number":"0001437749-23-017110","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BioLargo stockholders elect all 7 directors, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected; votes for ranged from 80.6M to 82.7M.","Advisory say-on-pay passed with 93.3% support (76.5M for, 2.8M abstain).","Ratification of Haskell & White LLP as auditor approved with 98.5% for (156.0M for).","Broker non-votes of 74.5M on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309445,"accession_number":"0001437749-23-017042","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo Q1 revenue up 78% QoQ; Pooph generates $27M D2C sales in 18 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 revenue up 78% QoQ and 130% YoY; net cash flow near breakeven; net loss ~$400k (non-cash).","Pooph, BioLargo's pet odor elimination product, generated $2.8M in 2022 and $3.1M in Q1 2023 for ONM Environmental.","Pooph D2C sales reached $27M with 814,000 orders; 21% repeat customers; shipped over 1 million bottles.","Management cautions Q2 revenue will be lower due to Walmart inventory stocking normalization.","ONM Environmental expanding into automotive, wastewater, and other industrial odor/VOC markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309444,"accession_number":"0001437749-23-016721","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo files slides for annual meeting; no material financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing reports Regulation FD disclosure of presentation slides at annual stockholder meeting on June 6, 2023.","No financial figures, operational updates, or guidance changes were provided in the filing or readable exhibit.","The exhibit is an image slide deck; content could not be extracted for specific metrics.","This is a routine procedural filing with no apparent new material information for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309443,"accession_number":"0001437749-23-015141","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents slides at May 18, 2023 earnings call; no financial details in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held earnings call on May 18, 2023.","Slide deck presentation was furnished as Exhibit 99.1.","Specific financial results or forward-looking statements are not included in the text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309442,"accession_number":"0001437749-23-013164","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo CEO projects Q1 revenue near $4M, Pooph sales driving growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2022 company-wide revenue grew 132% QoQ; Q1 2023 revenue expected just under $4M (3x YoY).","Pooph (pet odor product) in ~1,500 Walmart stores; expansion into remaining two-thirds expected 3-6 months.","PFAS remediation project estimated at $50-70M; first customer in phase two with 38 distribution partners.","Acquired sodium sulfur battery tech from University of Tennessee; building small manufacturing facility in Oak Ridge, TN.","Positive cash flow achieved in Q4 and Q1 2023; company near profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309441,"accession_number":"0001437749-23-009224","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents slides at Q1 2023 earnings call; no specific results in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company furnished an image-based slide deck as Exhibit 99.1 under Regulation FD.","Actual financial performance or material updates are not extractable from the provided filing content.","Slides were presented at the April 3, 2023 earnings call; details are unavailable in this 8-K text.","Confidence in summarizing news is low due to absence of numerical data in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3742000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328168,"accession_number":"0001437749-23-007938","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioLargo extends CFO Charles Dargan's engagement through Jan 2024; grants option for 300,000 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Charles K. Dargan II's engagement extended one year to January 31, 2024.","Compensation: option to purchase 300,000 shares of common stock at $0.20/share.","Option vests monthly (25,000 shares/month) starting March 21, 2023; expires in 10 years.","No cash compensation; CFO eligible for business expense reimbursement (historically not requested).","Prior extension expired January 31, 2023; agreement may be terminated on 30 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328167,"accession_number":"0001437749-23-007120","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo expects Q1 2023 revenue >4x YoY, seventh consecutive quarterly growth record","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 preliminary revenues expected to surpass Q4 2022 record; QoQ growth >50%.","Revenue driven by Pooph pet-odor product from Ikigai Marketing Works.","Company not yet profitable but net losses trending down as revenue increases.","2022 preliminary YoY revenue growth at least 125%; eighth consecutive annual growth.","Company expects to file 2022 annual report by end of March; earnings call April 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345824,"accession_number":"0001437749-22-029358","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioLargo secures $10M equity line from Lincoln Park Capital; issues 1.25M commitment shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BioLargo entered purchase agreement with Lincoln Park Capital for up to $10M of common stock over 36 months.","Company may sell shares at its discretion; Lincoln Park obligated to purchase subject to conditions.","As consideration, BioLargo issued 1.25M commitment shares and will pay $250k cash fee after $3M in sales.","Proceeds will be used for working capital and general corporate purposes.","Stock sales capped at 4.99% beneficial ownership; no short sales allowed by Lincoln Park."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345823,"accession_number":"0001437749-22-025632","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BioLargo appoints Linda Park and Christina Bray to board; Runyan and Roberts retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Linda Park, corporate secretary of Edwards Lifesciences, and Christina Bray, CEO of Bluedot Energies, join board effective Nov 1, 2022.","John S. Runyan and Kent C. Roberts II retired after over a decade; will remain as advisors.","New directors receive options to purchase 100k shares at $0.244 and quarterly board fees of $15,000 in options.","Both appointed to Audit, Compensation, and Nomination committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345822,"accession_number":"0001437749-22-025161","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports Q3 2022 revenue of ~$1.5M, up 111% YoY; record quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue approximately $1.5M, 13% sequential increase from Q2 and 111% YoY gain.","Preliminary results subject to review by independent registered public accounting firm.","POOPH pet odor product expected to launch in major retailers in Q4 2022.","First PFAS removal project at large industrial site advancing through multi-phase plan.","Company says it has locked in record growth rate for full year 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3786000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362242,"accession_number":"0001437749-22-019059","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo Q2 2022 revenue ~$1.3M, up 185% YoY; preliminary figures","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q2 revenue ~$1.3M, up 37% sequentially and 185% vs Q2 2021.","Growth driven by POOPH retail launch, PFAS treatment tech, waste-to-energy project.","National nuclear fuel innovator prototype project expected to expand after successful Phase 1.","Full Q2 results due in Form 10-Q by Aug 15, 2022; figures preliminary and unaudited.","Company plans investor webcast shortly after 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2287000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381769,"accession_number":"0001437749-22-014518","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"BioLargo shareholders approve increase in authorized shares to 550M and authorize reverse stock split","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common shares increased from 400M to 550M, effective June 7, 2022.","Board authorized to implement a reverse stock split at a ratio between 1:4 and 1:25 at its discretion.","All seven director nominees elected; advisory say-on-pay passed with 84.3M for, 9.8M against.","Ratification of Haskell & White LLP as auditor for FY2022 approved with 151.2M for.","Reverse split proposal passed with 136.2M for, 16.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381768,"accession_number":"0001437749-22-014090","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo files 8-K for annual meeting slide presentation; no text content available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Item 7.01 to disclose slides presented at June 2, 2022 annual meeting.","Exhibit 99.1 is an image-only slide deck; no textual data extracted from filing.","No specific financial or operational updates can be derived from the provided exhibit.","Company common stock trades on OTCQB under ticker BLGO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381767,"accession_number":"0001437749-22-013035","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports record Q1 revenue of $965k; ONM subsidiary turns first profitable quarter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record company-wide Q1 revenue $965k (+69% YoY); ONM Environmental revenue $598k (+87%) with $13k operating profit (first profitable quarter).","Engineering subsidiary revenue $355k (+177% YoY); operating loss narrowed to $35k from $183k.","PFAS AEC solution: in-house pilot completed; commercial trial with SoCal municipal agency planned; customer pipeline potentially >$90M.","Garratt-Callahan minimal liquid discharge system passed factory acceptance testing; commercial rollout to begin.","Engineering subsidiary hired for waste-to-energy plant feasibility study in South America; project cost >$500M; engineering portion ~10%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381766,"accession_number":"0001437749-22-009273","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports record Q1 2022 revenue of ~$900k; awarded feasibility contract for waste-to-energy plant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2022 revenue approx. $900k, up ~60% YoY; ONM Environmental record ~$550k, engineering subsidiary ~$350k.","Awarded feasibility study contract for a waste-to-energy conversion plant in South America, site ~296 acres, processing >2M tons MSW annually.","Potential total capital outlay for plant could exceed $500M; if developed, could keep BioLargo team busy for ~4 years.","Additional channel partnerships for PFAS treatment system in negotiation; partnerships with Garratt-Callahan and Ikigai.","Preliminary revenue figures unaudited and subject to change; full Q1 report expected May 16, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381765,"accession_number":"0001437749-22-008195","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).","Net loss reduced 29% to $6.9M, including $1.9M non-cash option expense and $342K impairment.","Total debt slashed from $2.9M to $681K; total liabilities down from $5.2M to $2.1M.","AEC PFAS treatment passed tests with municipality and federal agency; Garratt-Callahan MLD prototype completed.","Ikigai partnership for pet odor product exceeds initial projections; Clyra's Bioclynse secures two hospital customers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":965000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399749,"accession_number":"0001437749-22-007109","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioLargo extends CFO engagement through Jan 2023; grants 300k-share option at $0.24","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Charles K. Dargan II engagement extended one year to January 31, 2023.","Sole compensation: option to purchase 300,000 shares (25,000/month) at $0.24 per share.","Option vests monthly beginning March 2022; no cash compensation for the term.","Option granted under 2018 Equity Incentive Plan, expires ten years from grant date.","Either party can terminate the agreement with 30 days' written notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399748,"accession_number":"0001437749-22-005539","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"BioLargo unwinds 2018 Scion deal, transfers SkinDisc IP back, cancels $1.25M note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BioLargo and Clyra assign SkinDisc IP (patents, trademark) back to Scion; Scion keeps 2M BioLargo shares.","Scion forgives $1.25M promissory note principal ($1.007M outstanding) plus $152,716 accrued interest.","Scion returns 31,000 Clyra shares; Clyra cancels $305,450 in consulting debts owed to Brown, Rhodes, Liden.","Spencer Brown resigns from Clyra board; five-year non-compete on copper-iodine vs SkinDisc tech.","Mutual releases of all claims; BioLargo converts $633,091 Clyra advances into 2,042 Clyra shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}